To this end, the antibody blockade of IL-12p35/IL-12Rβ2 alone or in combination with existing IL-12p40/IL-12Rβ1 therapies may achieve better therapeutic outcomes in the treatment of human inflammatory conditions, including bacterial-induced colitis. This evidence concerns the gene IL12RB1 and colitis.